Recent Headlines
Within Biotechnology
Scintica Instrumentation and Aspect Imaging Announce Exclusive Agreement for Pre-Clinical MRI Imaging Products
Scintica Instrumentation Inc. is excited to announce its exclusive distribution agreement with Aspect Imaging for the M-Series(TM) MRI systems for scientific research. With more than 100 MRI installations worldwide, Aspect’s compact MRI systems are self-shielding, cryogen free and do not need... - September 18, 2019 - Scintica Instrumentation
DNAtix Launches Free Anonymous Genetic Vault
Digital DNAtix Ltd., the Israeli cyber genetics startup, has announced the first free anonymous genetic vault service. DNAtix developed the Cyber Genetics Smart Platform for Digital Genetics. Lack of privacy is currently a barrier for so many people who want to have their DNA tested but are afraid to give their genetic data away. As of today anyone can anonymously upload their raw file from 23&Me and Ancestry.com onto the DNAtix platform. - September 17, 2019 - Digital DNAtix Ltd.
Cambridge Cider Social Invites You to Celebrate Autumn by Tasting Hard Ciders and Donuts at a Fun Outdoor Festival
On October 24, 2019 join the ALS Therapy Development Institute in Cambridge for an outdoor celebration of autumn with hard cider, apple cider donuts, seasonal snacks, music, and fun – all in support of a great cause. - September 10, 2019 - ALS Therapy Development Institute
Paras Biopharmaceuticals Successfully Develops Cytofold StructQuant® Technology for Cytoplasmic Disulphide Formation, (for Active Folding) for Complex Therapeutic Protein
Paras Biopharmaceuticals Finland Oy is pleased to announce that its proprietary technology, Cytofold StructQuant®, is established for the high-level expression of homogeneously folded disulfide bond containing proteins in the cytoplasm of E. Coli. The technology offers all cost benefits of... - September 10, 2019 - Paras Biopharmaceuticals Finland Oy
FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension
Vascular Biosciences (VBS) is pleased to announce the receipt of a Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) for the Endoarterial Biopsy Catheter (EABC) to take pulmonary artery biopsies in patients who have Group 1 pulmonary arterial hypertension... - September 06, 2019 - Vascular BioSciences, Inc
Global Regenerative Group & Kanfit3D Enter Into Distribution Partnership
Pleased to announce a new distribution partnership between Global Regenerative Group, a company which has developed extensive experience in the most advanced medical device industries, and Kanfit3D. - September 05, 2019 - Global Regenerative Group
Biosynthetic Technologies Inks Patent License Agreement with Cayman Chemical for the Global Pharmaceutical and R&D Markets
Biosynthetic Technologies (BT) today announced it has signed on with Cayman Chemical for the production and distribution of novel Estolide compounds for pharmaceutical testing applications. BT is excited to partner with Cayman Chemical to provide discovery and pre-clinical development services to... - September 05, 2019 - Cayman Chemical Company
Thrivous Earns Better Business Bureau Accreditation
Better Business Bureau (BBB) of Utah has accredited Thrivous. After review, BBB determined that Thrivous meets its Standards for Trust: build trust, advertise honestly, tell the truth, be transparent, honor promises, be responsive, safeguard privacy, and embody integrity. Thrivous has committed to... - September 04, 2019 - Thrivous
CrystalGenomics Receives Orphan Drug Designation from the US FDA for CG-745 in Pancreatic Cancer
CrystalGenomics, Inc. (KOSDAQ: 083790) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of... - August 30, 2019 - CrystalGenomics, Inc.
Dr. David Dayton Joins Thrivous Science Advisor Board
Dr. David Dayton has joined the science advisor board at Thrivous, the human enhancement company. The board informs ongoing product and service development, reflecting Thrivous' commitment to guidance from consensus science in its mission to help customers access technology with the greatest... - August 28, 2019 - Thrivous
Thrivous Upgrades Clarity with Bioavailable Vitamin B Complex
Thrivous, the human enhancement company, has upgraded Clarity, the daily nootropic, to include bioavailable Vitamin B Complex. Clarity is a cognitive enhancement supplement that Thrivous developed to improve focus, memory, and mood. Thrivous designed formula 2 of Clarity to support brain function... - August 21, 2019 - Thrivous
Zifo RnD Solutions and Scilligence Announce Strategic Partnership
Zifo RnD Solutions and Scilligence Corporation announce a strategic partnership that enables Zifo to provide System Integrations Solutions for Scilligence suite of integrated informatics solutions. The partnership will help clients to easily select, evaluate, and implement solutions that fit their... - August 18, 2019 - Zifo
New Research Benchmarks Clinical Investigator Satisfaction with Pharma Sponsors and Central Laboratories
8-year Study Tracks Central Lab Performance and Identifies Covance as Leading the Way in Clinical Investigator Satisfaction. - August 13, 2019 - Life Science Strategy Group, LLC
Thrivous Launches Alpha, the Extended Daily Nootropic
Thrivous, the human enhancement company, has developed and brought to market Alpha, the extended daily nootropic. Alpha is designed for daily use to support long-term brain function. It is also designed to complement Clarity, Serenity, and Surge, nootropics previously developed and brought to... - August 11, 2019 - Thrivous
Arteric Named a Top 100 Healthcare Marketing Agency by MM&M
Latest accolade follows a year of 30% revenue growth and thought leadership. - August 09, 2019 - Arteric
Advances in Medicine Cause New, Groundbreaking Drug by Quantum Genomics (QNNTF) to Help with Chronic Hypertension
Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system. It is estimated that there are around 150 million people... - August 05, 2019 - Quantum Genomics
Global Regenerative Group Becomes Global Partner for Pharmaceutical Wholesaler Prosupplier GmbH Representing Their CureOs® Synthetic BONE GRAFT
Global Regenerative Group, developer and global distributor of new and innovative products in the field of Regenerative Medicine, today announces its partnership with Prosupplier GmbH, a pharmaceutical wholesaler with an experienced and specialist team, whose products include CureOs® Synthetic BONE GRAFT. - August 02, 2019 - Global Regenerative Group
Thrivous Launches Surge, the Acute Nootropic
Thrivous, the human enhancement company, has developed and brought to market Surge, the acute nootropic. Surge is designed for occasional use to increase energy and focus, and to reduce side effects from caffeine. It is also designed to complement Clarity and Serenity, nootropics previously... - August 01, 2019 - Thrivous
Brewing a Cure 4 ALS Fundraiser Invites You to Enjoy Regional Beers and Wines While Fundraising for ALS Research
On Saturday, August 10, 2019, the first-ever Brewing a Cure 4 ALS fundraiser will be held at Technology Square in Cambridge, MA. Brewing a Cure 4 ALS invites community members to enjoy craft beer, wine, music, and food with the goal of raising money for ALS research at the ALS Therapy Development... - July 31, 2019 - ALS Therapy Development Institute
On August 18, Wear Your Nerdiest Costume and Run for a Great Cause at the Race 4 Research 5K in Cambridge
On Sunday, August 18, the ALS Therapy Development Institute (ALS TDI) will host the annual Race 4 Research 5K and Walk in Technology Square, Cambridge. The event will feature a chip-timed nerdy 5K road race (costumes encouraged), a 4-mile ALS awareness walk and wheelchair ride along the Charles,... - July 26, 2019 - ALS Therapy Development Institute
Hans Kaspersetz Shares Arteric's Approaches to Leveraging Artificial Intelligence in Healthcare Marketing at Digital Pharma West
Two Case Studies Illustrate the Impact of AI on Accelerating Business, and the Insights That Result - June 23, 2019 - Arteric
Multiplex ELISAs Offer Powerful Profiling Capabilities
Cayman now offers multiplex immunoassay technology powered by Quansys Biosciences. This line of fully quantitative Q-Plex™ multiplex ELISAs and chemiluminescent Q-View™ imagers provides a highly sensitive means to simultaneously measure multiple markers using a single sample. - June 22, 2019 - Cayman Chemical Company
BraveHeart Wireless Announces FDA Clearance of the BraveHeart™ Life Sensor Cardiac Monitoring System
The BraveHeart™ Life Sensor Cardiac Monitoring system has been cleared for use in health care settings. The Life Sensor monitoring system securely captures patients’ heart rate and EKG data, and transmits the data to health care providers in real time. More than 28 million Americans diagnosed with heart disease may benefit - with this number growing each year. - June 20, 2019 - BraveHeart Wireless Inc.
Orangetheory Fitness and Augie’s Quest Collaboration Funds Innovative Research at the ALS Therapy Development
This past May over 1,100 members of Orangetheory Fitness ran, rowed, and lifted, earning “splat points,” which they turned into $4.5 million in donations for Augie’s Quest to Cure ALS. With this donation Augie’s Quest is supporting non-profit biotech, the ALS Therapy Development Institute (ALS TDI), to fast track cure-driven drugs for ALS. - June 20, 2019 - ALS Therapy Development Institute
AMT Partners with Medicare for Educational Webinar: Critical Medicare Documentation Requirements for Wound Care Residents
American Medical Technologies has partnered with Durable Medical Equipment Medicare Administrative Contractors (DME MACs), Noridian Healthcare Solutions and CGS Administrators, to host a live educational webinar covering Medicare’s documentation requirements for wound care residents. - June 18, 2019 - American Medical Technologies
The OMEGATOF, a Fully Integrated Benchtop Spectrometer Instrument for High-Mass MALDI Applications with the Power of CovalX Technology Inside
CovalX has partnered with Shimadzu Scientific Instruments to offer the OMEGATOF, an integrated MALDI solution for ultra high-mass detection. With a focus on the detection of large molecules, including biotherapeutics, protein complexes, aggregates, and antibody-antigen interactions in a benchtop... - June 13, 2019 - CovalX
New Research Benchmarks Pharma’s Changing Utilization of Real-World Evidence (RWE) and Its Impact on Contract Research Organizations (CROs)
Study Tracks Utilization of Real-World Data (RWD), Real-World Evidence (RWE) and Supportive Services and Implications to CROs. - June 11, 2019 - Life Science Strategy Group, LLC
Ingredient Alliance Announces Launch of Pharma Grade CBN/CBG/THCV and Early Harvest Biomass
Designer Cannabinoids take center stage at Ingredient Alliance. - June 11, 2019 - Ingredient Alliance
Global Regenerative Group (GRG) Announced That the Global Regenerative Academy Has Been Launched
The Global Regenerative Academy is an integral part of the Global Regenerative Group, a privately-held medical technologies company specializing exclusively on Regenerative Medicine and stem cell technologies, products, and therapies that significantly enhance the body’s natural healing ability. - June 06, 2019 - Global Regenerative Group
Matreya, LLC is Now a Part of Cayman Chemical Company to Better Serve the Lipid Community
Cayman Chemical, an industry-leading supplier of bioactive lipids, analytical standards, and contract lipidomic services, announced today that it has acquired Matreya, LLC, a lipid biochemical company located in State College, Pennsylvania, with strengths in synthesis, extraction, and purification of natural products. Matreya stocks a wide selection of high-purity sphingolipids, phospholipids, fatty acids and esters, and sterols to be used as research standards. - June 05, 2019 - Cayman Chemical Company
BPOG Extractables Testing of AdvantaPure(R)’s Key Silicone and TPE Tubing Products is Complete; Test Results Help Drug Manufacturers Compare Tubing
BioPhorum Operations Group extractables testing was recently completed on several of AdvantaPure’s tubing and hose products. The fluid transfer products are typically used in biopharm and pharmaceutical manufacturing processes. The Group’s standardized extractables test protocol was followed and performed by an independent lab and involved testing to four different exposure times as long as 70 days. The comprehensive testing was undertaken by AdvantaPure to meet customer requests. - May 31, 2019 - AdvantaPure
Pillar Clinical Research Announces New Ratings Initiative: Pillar Precision
The Dallas based research company plans to roll out a new clinical rating training program, Pillar Precision. The program includes a clinician guide featuring best practices for specific CNS indications, placebo response training, malingering detection, data-driven decision making, and multi-site... - May 24, 2019 - Pillar Clinical Research
Apostle Inc. Completes Series A Financing Led by ShangBay Capital
Apostle Inc. is pleased to announce the completion of its series A financing, raising $3.3 million. The investment round is led by ShangBay Capital, a Silicon Valley-based venture capital firm, focused on investing in early stage medical device and biotech companies. Three other Silicon... - May 24, 2019 - Apostle Inc
First Responders Unite to Arrest and Extinguish ALS
Inaugural Arrest and Extinguish event at Tanglewood raises over $50,000 for ALS research. - May 23, 2019 - ALS Therapy Development Institute
First Responders Unite to End ALS at Inaugural Arrest & Extinguish Event
On May 18th, first responders will unite for a tug-of-war event at Tanglewood to raise money for ALS research. - May 11, 2019 - ALS Therapy Development Institute
Arteric Advances Healthcare Marketing and Engagement Campaigns at Biopharma eMarketing Summit
President and Chief Strategist Shares Two Case Studies That Illustrate How to Leverage Artificial Intelligence to Achieve Business Goals. - May 10, 2019 - Arteric
Scientists at AbboMax Developed Antibodies Against PINK1 and Parkin to Study Parkinson’s Disease
A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease (PD). These phosphospecific and paired antibodies would be useful tools for studies of PINK/Parkin pathways and signaling in PD. AbboMax has been developing & manufacturing high performance immunoassay reagents for many years in California. AbboMax specializes in high-quality custom service and products focusing on antibody and assay development. - May 09, 2019 - AbboMax, Inc.
Eurofarma Synapsis Receives Registrations Until June 21
Sustainable entrepreneurship platform in Latin America in partnership with Endeavor, encourages innovation in health area. - May 09, 2019 - Eurofarma
Oxytocin Exposure During Labor Influences Offspring Development: Offspring Demonstrated Long-Term, Epigenetic Changes in Brain & Behavior After a Single Administration
A research team from the Kinsey Institute, Indiana University, the University of Virginia and Northeastern University recently discovered that a single exposure to oxytocin near the time of birth can have effects in the offspring, including increases in social behaviors that may persist into adulthood. - May 07, 2019 - Kinsey Institute
Reuters to Make Documentary on Paras Biopharmaceuticals Finland Oy – Innovations in Biologics: Insights of a Leading Expert
Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected the Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions. The documentary is part of... - May 07, 2019 - Paras Biopharmaceuticals Finland Oy
May is ALS Awareness Month - #AskMeAboutALS
May is ALS Awareness Month. The ALS Therapy Development Institute is inviting the general public to participate, and hoping to inspire a larger dialogue around ALS, through #AskMeAboutALS. - May 01, 2019 - ALS Therapy Development Institute
NanoCellect Biomedical Begins Distribution to Europe
NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced an exclusive distribution agreement with Basel, Switzerland-based Bucher Biotec AG. The agreement covers sales in Switzerland of NanoCellect’s... - May 01, 2019 - NanoCellect
MD Stem Cells New Alzheimer’s Treatment Shows Early Benefits
Initial memory improvements following ACIST stem cells may hold promise for ALZ. - April 24, 2019 - MD Stem Cells
Texas Clinical Research Company Announces Expansion and New Quality Assurance Initiative
Pillar Clinical Research (Pillar), with a focus on early and late stage CNS drug development, opens two new US research facilities in Illinois and Arkansas and adds Director of Quality Assurance. Dr. Andrew Kim joined the Chicago team in September of 2018, and has spent over 5 years in clinical... - April 18, 2019 - Pillar Clinical Research
Zifo RnD Solutions Announces Launch of Sci-Desk
Zifo RnD Solutions announced the launch of its latest product Sci-Desk, an on-demand, cloud-based, Scientific Application Support-in-a-box. Sci-Desk offers comprehensive managed services for Scientific & lab computing systems spanning Discovery, R&D and Manufacturing industries. “Sci-Desk is a first of its kind in the Life Science R&D Spectrum. Sci-Desk brings on-demand, scalable, customizable and secure support to scientific applications,” said Raj Prakash, CEO/Co-Founder of Zifo RnD Solutions. - April 18, 2019 - Zifo
YouScript and Genome Medical Announce Partnership to Provide Clinical and Analytics Support for Genetic Risk Management
Connecting precision medicine analytics and genetic services - April 03, 2019 - YouScript
Standigm Raises US $11.5 Million in Series B Round Funding to Advance Its AI-Powered Drug Pipelines Toward License-Out
Standigm, an AI-powered drug discovery company, has raised $11.5 million in a Series B funding round. The funds will be used to scale the AI technology platforms and advance its drug discovery pipelines for untreatable diseases. - March 29, 2019 - Standigm
Are Antioxidants the Solution to Burning and Itchy Eyes?
A recently published study in The Ocular Surface journal authored by Experimentica Ltd. in collaboration with researchers from Loyola University Chicago and the University of Missouri – Kansas City suggests that a topical antioxidant formulation can improve the pathological signs associated with dry-eye disease. - March 26, 2019 - Experimentica Ltd
Huntington Study Group Achieves 100th Credentialed Research Site Milestone
The Huntington Study Group (HSG), a world leader in spearheading research and conducting clinical trials in Huntington disease (HD), is excited to announce that it has credentialed Inland Northwest Research, LLC as the 100th HSG site in North America. “On behalf of myself and our site, I... - March 25, 2019 - Huntington Study Group
Daryn Henry Joins Arteric as Creative Director
Veteran Digital Communicator Brings Decades of Award-Winning Experience to Boundary-Pushing Agency. - March 15, 2019 - Arteric